Delivery Order SPE2DB20D1109-SPE2DB25FP09W
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) with a ceiling value of $12,701.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under the company's larger...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 21, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) with a ceiling value of $14,886.82. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made without set-aside designations, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $13,882.26 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a discrete delivery of this specialty...
- The Defense Logistics Agency awarded a delivery order valued at $10,334.40 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory care. This firm fixed-price delivery order, awarded on July 17, 2025, with an ultimate completion date of July 18, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $2,599.62 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,152.50 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Pulmozyme 1 mg/ml ampule 2.5ml. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on September 17, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency has awarded a delivery order valued at $18,388.41 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml vials). This firm fixed-price, non-set-aside delivery order was awarded on May 8, 2025, with an ultimate completion date of May 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This award represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL pharmaceutical product. This is a firm fixed price delivery order with a ceiling value of $2,583.60 and an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product commonly used in cystic fibrosis treatment. This non-set-aside, firm fixed-price delivery order has a ceiling value of $16,287.62 and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP09WDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5mL with a ceiling value of $4,280.40. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is scheduled for ultimate completion on May 21, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as the primary pharmaceutical supply vehicle for military and federal healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that serves as a critical vendor for the Defense Logistics Agency's medical supply chain, providing a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. The company's delivery orders under this IDC demonstrate consistent capability to fulfill federal procurement requirements across diverse therapeutic domains, with awards ranging from small-value transactions to substantial orders exceeding $45,000. This particular delivery for the pulmonary disease treatment Pulmozyme represents routine replenishment of pharmaceutical inventory supporting Defense Health Agency and other federal healthcare system needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 5/20/25 |